|
| Status |
Public on Dec 07, 2016 |
| Title |
4T1-Spleen-animal-32 |
| Sample type |
RNA |
| |
|
| Source name |
Spleen from mouse with mammary tumour cell line 4T1 grown in vivo subcutaneously on back of BALB/c mouse
|
| Organism |
Mus musculus |
| Characteristics |
cell line: 4T1
experimental group: 4T1_Sp
tissue: Spleen
mouse strain: Balb/C
tissue of origin: Breast
Sex: Female
animal number: 32
sample number: 78
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA was extracted from the cell lines and from the tumor, spleen and lymph node tissues from each model using RNAStat 60 (Amsbio) and quality of total RNA was determined using a 2100 Bioanalyzer (Agilent). Samples were amplified using the WT-Ovation Pico amplification kit (NuGEN Technologies).
|
| Label |
biotin
|
| Label protocol |
cDNA was fragmented and labelled using the FL-Ovation cDNA Biotin Module V2 (NuGEN Technologies).
|
| |
|
| Hybridization protocol |
Samples were hybridized to Mouse Exon 1.0 ST arrays (Affymetrix) according to NuGEN guidelines for Affymetrix GeneChip® arrays.
|
| Scan protocol |
Arrays were washed, stained and scanned in accordance with the Affymetrix GeneChip Whole Transcript (WT) Sense Target labelling Assay Manual.
|
| Description |
4T1-S32
|
| Data processing |
Raw microarray data for the in vitro and in vivo samples underwent Robust Multichip Algorithm (RMA) pre-processing/normalisation in Omicsoft ArrayStudio. 1192934 exon probes remained with a probe detection p value <= 0.05.
|
| |
|
| Submission date |
Aug 11, 2016 |
| Last update date |
Dec 07, 2016 |
| Contact name |
John Prime |
| E-mail(s) |
john_e_prime@yahoo.co.uk
|
| Organization name |
Medimmune
|
| Department |
Oncology Research
|
| Street address |
Aaron Klug Building
|
| City |
Cambridge |
| ZIP/Postal code |
CB21 6GH |
| Country |
United Kingdom |
| |
|
| Platform ID |
GPL6096 |
| Series (2) |
| GSE85507 |
Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery [exon array] |
| GSE85509 |
Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery |
|
